<DOC>
	<DOCNO>NCT02624895</DOCNO>
	<brief_summary>This national , multicentric , prospective , observational trial . The decision prescribe FOLFOX plus panitumumab FOLFOX plus cetuximab must freely take clinician prior study entry patient include . Each physician see his/her patient within context routine visit , without special visit organise purpose study . Therefore , doctor-patient relationship patient follow-up modify . Physicians totally free decide patient ' therapeutic management . EORTC QLQ-C30 DLQI questionnaire complete patient baseline ( Day 1 Cycle 1 ) , first day every cycle ( every 2 week ) thereafter , `` end treatment visit '' ( 28 day ( +/- 3 day ) last cycle ) . Questionnaires complete start visit , study related procedure do . Before every cycle , adverse event record grade accord NCI CTCAE v4.0 . Treatment 's modification term cycle ' delay , dose reduction drug ' interruption record . Concomitant approach prevent treat dermatological toxicity treatment register .</brief_summary>
	<brief_title>ObservationaL Study Qol RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX -1st Line</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult ( &gt; = 18 year old ) RAS wildtype metastatic colorectal cancer patient candidate receive FOLFOX plus panitumumab FOLFOX plus cetuximab upfront treatment per clinical practice Willingness ability comply protocol Written inform consent study procedures Patients receive treatment clinical investigation may include study Previous treatment antiEGFR monoclonal antibody Contraindication study treatment ( i.e . relevant comorbidities contraindicate use fluoropyrimidines and/or oxaliplatin and/or antiEGFR monoclonal antibody ) Coexisting pathology may contraindicate use study drug ( eg . Neuropatic disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic colorectal cancer gene RAS mutate `` WILD TYPE ''</keyword>
</DOC>